1 / 52

Hereditary tumours to be aware of

Hereditary tumours to be aware of. Gerd JACOMEN Dept. of Pathology. What is the link?. Malignant tumours are caused by genetic changes Hereditary diseases are genetically transmitted Familial clusters of malignancies. Sporadic/Familial genetic changes.

jenna
Download Presentation

Hereditary tumours to be aware of

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hereditary tumours to be aware of Gerd JACOMEN Dept. of Pathology

  2. What is the link? Malignant tumours are caused by genetic changes Hereditary diseases are genetically transmitted Familial clusters of malignancies

  3. Sporadic/Familial genetic changes • Mutation can be sporadic in 1 somatic cell: epigenetic • Mutation can be present in a germ cell: • Germline mutation • All cells derived from that cell will harbour the mutation • Can be inherited or new

  4. Familial tumours of the uterine corpus 95% are sporadic 5% are familial Lynch syndrome Variant: Muir-Torre syndrome Cowden syndrome BRCA1

  5. HNPCC Hereditary nonpolyposis colorectal cancer syndrome Lynch Autosomal dominant Germline mutations in mismatch repair genes Genes that are responsible for correcting errors (mismatches) during DNA replication

  6. Caretaker genes Normal function: helps genome to be stable during replication DNA Mismatch repair genes Microsatellites: repetitive DNA sequences Prone to replication errors Normally corrected by Mismatch repair system

  7. Microsatellite instability Whenever Mismatch repair genes do not function Result: microsatellites are no longer “stable” during replication Hence: Microsatellite Instable MSS, MSI-Low, MSI-High

  8. Involved genes MLH1, MSH2, MSH6, PMS2

  9. Are all MSI-High tumours Lynch? • 20-25% of all endometrial Ca are MSI-H • 75% are sporadic: epigenetic silencing of MLH1 (promotor methylation) • Remaining cases: mostly Lynch associated • Ca 2% of all endometrial cancers! • Age dependent: 9% in younger patients

  10. Recognising is important Patient and family have increased risk for malignancies Genetic counseling/testing Gynecologic malignancy is sentinel cancer in 50%

  11. Features that raise suspicion Familial anamnesis Clinical Gross Histology

  12. Familial anamnesis Not only gynecologic malignancies Not only females Take your time!

  13. Malignancy in Lynch • Increased risk of multiple malignancies Colon Endometrium Ovary Stomach Urinary tract Hepatobiliary tract Small intestine Brain

  14. Clinical Other malignancies? Age BMI

  15. How to diagnose Lynch? Def: germline mutation in DNA mismatch repair genes Mutation analysis is definitive test Expensive and time consuming Patient consent needed Screening!

  16. Simple screening: immunohistochemistry • Using Ab against MLH1, PMS2, MSH2, MSH6: detection of MSI-H tumours • Sensitivity 91% • Specificity 83%

  17. IHC result Expression can direct mutational analysis + staining with all 4 Abs: no further testing (except if clinical suspicious)

  18. Importance of IHC result Loss of MSH2 and/or MSH6 is virtually diagnostic for Lynch! Loss of MLH1 or PMS2 can still be epigenetic (= not because of germline mutation)

  19. Advantage of IHC as screening Simple Inexpensive Readily available Can direct gene sequencing

  20. Disadvantages of IHC • Interpretation can be problematic • 10% of germline mutations remain undetected by IHC • Loss of expression can be epigenetic = not Lynch, but sporadic

  21. Breast Cancer and Lynch Breast Cancer Research 2012,14:R90 Breast Cancer Research 2012,14:110

  22. MSI in breast Ca 0-3% in sporadic breast Ca > 50% of breast Ca in Lynch syndrome mutation carriers

  23. Features of Lynch associated breast Ca Same age Same type Same grade Same stage Same receptor and HER2 status Same chemotherapy?

  24. Which endometrial Ca should be stained? < 50 ys Non-endometrioid Ca < 60 ys Lower uterine segment Multicentric or heterogeneity Peritumoral lymphocytes TIL > 42/10 HPF “hard to type” Ca Familial/personal history

  25. Hereditary tumours of ovary and fallopian tube 10% of all ovarian Ca are associated with inherited germline mutations BRCA1/2 Lynch

  26. Lifetime risk for mutation carriers BRCA1: 66% BRCA2: 10-20% MLH1/MSH2: 3-12% Global Western population <2%

  27. BRCA1/BRCA2 Inherited mutations in BRCA1 or BRCA2 genes BRCA1/BRCA2 act as tumour suppressor genes Autosomal dominant

  28. Tumour suppressor genes Normal function: gene encodes for protein involved in control of normal cell cycle Of each gene are 2 copies in a cell: 2 mutations are needed before the protein will not be encoded properly

  29. 2 mutations: 1 in each allele First: makes cell “vulnerable” Mutation on second allele: no longer synthesis of normal protein No longer normal function

  30. Frequency of BRCA-mutation 0.3% of women is carrier of the mutation 2% of Ashkenazi jews

  31. Histology of BRCA associated ovarian Ca Type: Serous Grade: High Stage: Advanced BRCA1 = BRCA2

  32. What is not associated with BRCA? Mucinous Ca If high grade/high stage: think of metastasis first! Low grade serous Borderline serous

  33. BRCA1/2 associated ovarian/tubal Ca Since high risk of Ca if carrier: prophylactic BSO At age 35 ys, or after child-bearing is completed

  34. Prophylactic BSO Occult cancers Tubal intraepithelial Ca

  35. Occult cancers = Ca in absence of preoperative evidence of malignancy 4-10% of prophylactic BSO Can measure up to 5 cm

  36. Where? Most are located at tubal fimbriae Due to oxidative stress at ovulation

  37. Prognosis Even little tumours may metastasise Complete staging necessary as for serous Ca ovary

  38. Precursor lesions Tubal Intraepithelial Carcinoma (TIC) In 8% of prophyactic BSO + for p53 High Ki67 (>50%)

  39. Prognosis Uncertain Some cases may metastasise Chemotherapy not considered necessary

  40. Precursor lesions of TIC SCOUT p53 signature Proliferative p53 signature Importance in routine setting unknown

  41. p53 signature p53 Ki67

  42. BRCA1/2 and breast cancer Lifetime risk of breast Ca if carrier: BRCA1: 70% BRCA2: 45% Other risk factors remain important

  43. Histopathologic features of BRCA associated breast Ca Invasive Ca of no special type (BRCA1) Grade 3 Triple negative p53 positive Basal CKs positive

  44. Hereditary diffuse gastric cancer Families with diffuse gastric cancer and lobular Ca breast Germline mutations of CDH1 gene (E-cadherin)

  45. Diagnostic criteria ≥ 2 cases of diffuse gastric cancer in 1st or 2nd degree relatives, at least 1 diagnosed < age 50 or ≥ 3 cases of diffuse gastric cancer in 1st or 2nd degree relatives, regardless of age at diagnosis

  46. Breast cancer in HDGC Females in HDGC families are at increased risk of breast Ca Lifetime cumulative risk of 60% by age 80 Most are lobular Ca

  47. Gastric biopsy of patient with lobular Ca

  48. Atypical cells and signet cells in stroma

  49. Diagnosis? • Lobular Ca breast and gastric diffuse Ca are similar • Metastasis? • 2 separate primaries? • Treatment is completely different!

  50. ER

More Related